E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion by Morita, N et al.
In the United States and the European countries, prostate cancer
has become the second and third leading cause of cancer death
in men, respectively (Boring et al, 1993; Black et al, 1997).
Associated mortality in Japan has also increased in recent years
with the Westernization of dietary habits (Tominaga and Kuroishi,
1997). The continuing controversy as to whether PSA-based
screening and early detection of prostate cancer may contribute to
decreasing its morbidity and mortality (Hall, 1996; Smart, 1997) is
partly due to the difficulty in predicting biological potential.
Although clinical stage and grade have been widely utilized as
prognostic factors in prostate cancer, their value appears limited.
At every stage, both good and poor clinical courses are found
(Grayhack and Assimos, 1983). Furthermore, while the extremes
of tumour grade, e.g. well and poorly differentiated, are useful in
formulating a probable prognosis for patients (Grayhack and
Assimos, 1983), the majority of patients have moderately differen-
tiated or Gleason’s grade 5–7 tumours (Grayhack and Assimos,
1983; Carter and Coffey, 1989). Therefore, identification of new
markers which might accurately reflect biological aggressiveness
of prostate cancers remains a high priority.
E-cadherin is a Ca2+-dependent intercellular adhesion molecule
in epithelial cells which plays an important role in establishing
and maintaining intercellular connections and morphogenesis
(Takeichi, 1991). This transmembrane glycoprotein forms a
complex with catenins, which can be divided into a, b and g on
the basis of their electrophoretic mobilities (Ozawa et al, 1989).
E-cadherin binds directly to either b-catenin or g-catenin, whereas
a-catenin links the bound E-cadherin complex to the actin
cytoskeleton (Hinck et al, 1994).
It has been suggested that dysfunctional E-cadherin-mediated
cell adhesion is associated with tumour invasion and metastasis. In
vitro studies have shown that loss of E-cadherin expression is
correlated with an invasive phenotype (Behrens et al, 1989;
Vleminckx et al, 1991; Bussemakers et al, 1992) and aberrant
E-cadherin expression is associated with poor differentiation and
an invasive phenotype in several human cancers (Umbas et al,
1994; Syrigos et al, 1995; Siitonen et al, 1996; Wasielewski et al,
1997). Similarily, aberrant expression of membrane-bound a- and
b-catenin has been observed in cancer cell lines and tumour tissues
(Kadowaki et al, 1994; Matsui et al, 1994; Ochiai et al, 1994;
Pierceall et al, 1995; Rimm et al, 1995). Downregulation of these
catenins seems to be associated with dysfunction of E-cadherin-
mediated cell adhesion and increase of the metastatic potential of
cancer cells (Kadowaki et al, 1994; Matsui et al, 1994; Ochiai et
al, 1994; Pierceall et al, 1995; Rimm et al, 1995). Recent studies
have further revealed that free cytoplasmic b-catenin behaves
as an oncoprotein in the APC-b-catenin-Tcf pathway (Korinek
et al, 1997; Morin et al, 1997). It remains unresolved whether
membrane-bound b-catenin in the cadherin–catenin complex may
affect the free cytoplasmic b-catenin pool (Nakamura, 1997).
Coexpression of E-cadherin and a-, b- and g-catenin has been
studied in bladder and gastric cancers (Shimazui et al, 1996;
Jawhari et al, 1997), but not to our knowledge in prostate
neoplasms. Therefore the present immunohistochemical examina-
tion of E-cadherin and a, b, g-catenin levels in radical prostatec-
tomy specimens from 45 prostate cancer patients not undergoing
any preoperative treatment was performed. Particular attention
was concentrated on the correlation between expression pattern
and types of histopathologically defined tumour invasion.
MATERIALS AND METHODS
Tissue specimen
Tissue specimens were obtained from 45 patients with prostate
cancer who underwent radical prostatectomy in Nara Medical
University Hospital or its affiliated hospitals between January
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ranging from 54 to 76 years. Bone scan and CT scan of the pelvis
did not reveal any metastasis and none of the patients received
treatments such as androgen-deprivation therapy, chemotherapy or
radiation therapy before surgery.
Each specimen was serially cut at 5-mm intervals vertically to
the urethra. One slice of the whole prostate was fixed in 10%
neutral buffered formalin, embedded in paraffin, and sectioned at
5 mm and the remaining slices were frozen at –70°C for subse-
quent immunohistochemistry. Sections were stained with haema-
toxylin and eosin (HE) for mapping of cancer-affected areas.
The histological differentiation of prostate cancer was determined
according to the Gleason system (Gleason, 1977). Histopatho-
logical diagnosis was made by one pathologist (NK) to ensure
consistency.
Immunohistochemistry
Based on HE evaluation of formalin-fixed tissue, regions were
selected for immunohistochemistry from frozen specimens. The
seminal vesicles were excluded from immunohistochemical
analysis. Immunostaining for E-cadherin and the three types of
catenin was performed using a standard avidin–biotin immuno-
peroxidase technique. Antibodies used were HECD-1 (1:1000)
for E-cadherin (Takara, Shiga, Japan), anti-a-catenin (1:100),
anti-b-catenin (1:100) and anti-g-catenin (1:100) (Transduction
Laboratories, Kentucky, USA). Briefly, 5-mm frozen sections were
air-dried and fixed with 3% paraformaldehyde. After endogeneous
peroxidase was blocked using 0.3% hydrogen peroxidase in
methanol, non-specific staining was eliminated by 30 min of
incubation with normal horse serum. The sections were incubated
at 37°C with primary antibodies for 60 min, biotin-labelled
secondary antibody for 30 min and ABC complex for 30 min
(Vectastatin ABC kit, Vector Laboratories, Inc., CA, USA).
Peroxidase reaction was visualized with a solution of DAB
(diaminobenzidine tetrahydrochloride) supplemented with 0.01%
hydrogen peroxidase. The sections were counterstained with
haematoxylin, dehydrated and mounted.
Evaluation of immunostaining was done by two independent
observers (NM and MC) as follows: uniformly positive staining
was regarded as normal, while uniformly negative or heteroge-
neous (mixed populations of positive and negative cells) staining
as aberrant (Figure 1). Areas of benign prostatic hyperplasia or
normal prostatic glands adjacent to prostate cancers were used as
internal positive controls.
Statistical analyses
Correlation between expression of each molecule and clinico-
pathological parameters was evaluated using the c2 test.
Probability values < 0.05 were considered significant.
RESULTS
Histopathological findings for all cases are summarized in Table 1.
Very few lesions could be categorized as well-differentiated
(Gleason score 3–4) type (3/45, 7%), with the remainder being
equally divided into moderately differentiated (Gleason score 5–7)
and poorly differentiated (Gleason score 8–10) types (22/45, 49%
and 20/45, 44%, respectively). Capsular invasion was apparent in
almost half of all cases (22/45, 49%) with most of them being
extracapsular (16/22, 73%). Lymphatic duct were frequently
invaded (31/45, 69%), while vascular invasion was not frequent
(8/45, 18%). Seminal vesicle invasion and lymph-node metastasis
were also uncommon events (8/45, 18% and 3/45, 7%, respec-
tively) (data not shown).
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Figure 1(A) Normal immunostaining for E-cadherin in a prostatic
adenocarcinoma (Gleason score 6), magnification ´ 200.
(B) Heterogeneous immunostaining for a-catenin in a prostatic
adenocarcinoma (Gleason score 7), magnification ´ 200.
(C) Completely negative immunostaining for b-catenin in a prostatic
adenocarcinoma (Gleason score 9), magnification ´ 200Data for expression patterns of E-cadherin and the three types
of catenin are also summarized in Table 1. The frequencies of
normal and aberrant expression were, respectively, 24 and 21 for
E-cadherin, 23 and 22 for a-catenin, 26 and 19 for b-catenin, and 31
and 14 for g-catenin. Invading groups of cancer cells generally
showed the same expression pattern as primary nests. No correlation
with the preoperative PSA value was evident (data not shown).
Expression of E-cadherin was consistent with those of catenins in 31
cases (69%). Of the other 14 (31%), four showed normal E-cadherin
with aberrant expression of at least one type of catenin and 10
E-cadherin and catenin expression in prostate cancer 1881
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Table 1 Histopathological findings and E-cadherin and catenins expression in all prostate cancers
Gleason Capsular Lymphatic Vascular Expression
Case score invasion invasion invasion E-cadherin a-catenin b-catenin g-catenin
1 3 (–) (–) (–) N N N N
2 3 (–) (–) (–) N N N N
3 4 (–) (–) (–) N N N N
4 5 (+) (+) (–) A A A A
5 5 (+)a (+) (–) A A A A
6 5 (+)a (+) (–) N N N N
7 5 (+)a (+) (–) N N N N
8 5 (–) (–) (–) N N N N
9 6 (+)a (+) (+) N N N N
10 6 (+) (–) (–) A A A A
11 6 (–) (+) (–) N N N N
12 6 (–) (+) (–) N N N N
13 6 (–) (+) (+) N N N N
14 6 (–) (–) (–) N N N N
15 7 (+) (+) (–) A A A N
16 7 (+)a (+) (–) N N N N
17 7 (+)a (+) (+) N N N N
18 7 (+) (+) (+) A A A A
19 7 (–) (+) (–) N N N N
20 7 (–) (+) (–) N N N N
21 7 (–) (+) (–) N A A N
22 7 (–) (+) (–) N N N N
23 7 (–) (–) (–) N N N N
24 7 (–) (–) (–) A A N N
25 7 (–) (–) (–) A A N N
26 8 (+)a (+) (–) N N N N
27 8 (+)a (+) (–) N A A N
28 8 (+)a (+) (–) A A A A
29 8 (+)a (+) (+) A A A N
30 8 (+)a (+) (–) N N A A
31 8 (+)a (+) (+) A A N N
32 8 (–) (+) (–) N N N N
33 8 (–) (–) (–) A A A A
34 9 (+)a (+) (+) A A A N
35 9 (+)a (+) (+) A A A A
36 9 (+)a (+) (–) A A A A
37 9 (+)a (+) (–) N A A A
38 9 (+) (–) (–) A A N A
39 9 (–) (+) (–) A A A A
40 9 (–) (+) (–) A N N N
41 9 (–) (+) (–) N N N N
42 9 (–) (–) (–) A A A A
43 9 (–) (–) (–) A A N N
44 9 (–) (–) (–) A N A N
45 10 (+) (+) (–) A A A A
aCapsular penetration. N, normal expression; A, aberrant expression.
Table 2 Relationship between E-cadherin and catenin expression
E-cadherin Catenin expression
expression No. Na N+Ab Ac Significance
N2 4 2 0 31c2 = 28.45
A2 1 1 91 1 P < 0.0001
N, normal expression; A, aberrant expression. aa-, b- and g-catenin all normally expressed. ba-, b- and g-catenin aberrantly expressed
singly or in pairs.ca-, b- and g-catenin all aberrantly expressed.the converse (Table 2). Nuclear localization of b-catenin could not
be estimated in our samples because of the frozen sections and
haematoxylin counterstaining.
Expression of E-cadherin and the three types of catenin was
significantly correlated with histological differentiation (Table 3)
but not lymphatic or vascular invasion (data not shown). Aberrant
expression of the three types of catenin was associated with
capsular invasion (Table 4). In moderately differentiated cases,
aberrant expression of b- and g-catenin was associated with
capsular invasion, but that of E-cadherin and a-catenin was not
(Table 4).
DISCUSSION
Escape from primary nests as the initial step of cancer invasion
requires disruption of the normal cell–cell adhesion in the epithe-
lial tissue, which is dependent on the linkage between E-cadherin
and the actin cytoskeleton via catenins (Kadowaki et al, 1994).
Even if cadherin is present, intercellular adhesion is impaired if
the connections are disturbed (Kadowaki et al, 1994). Thus,
studying the patterns of both E-cadherin and catenins expression
in cancer tissues with respect to invasion is warranted. The current
study was the first, to our knowledge, to examine expression of
E-cadherin and a, b, g-catenin in prostate cancer using immuno-
histochemistry, although the relationship between E-cadherin and
a-catenin expression has been investigated (Umbas et al, 1997;
Richmond et al, 1997).
Our finding of association with differentiation is consistent with
previous reports (Kadowaki et al, 1994; Matsui et al, 1994; Umbas
et al, 1994; Rimm et al, 1995; Syrigos et al, 1995; Siitonen et al,
1996). The consistency in data for the four molecules is also in line
with earlier results. It has been reported that a- and g-catenin are
unstable in L cells lacking cadherin, but that they can be stabilized
by desmosomal cadherins and E-cadherin, respectively
(Nagafuchi et al, 1991; Kowalczyk et al, 1994). Thus catenins
expressed normally in 10 cases lacking E-cadherin might have
been stabilized by other molecules. Aberrant expression of three
types of catenin was also associated with capsular invasion,
although the significant relationship was retained only for b- and
g-catenin when restricted to moderately differentiated (Gleason
score 5–7) tumours. Of the four discrepant cases showing normal
expression of E-cadherin and aberrant expression of at least one
type of catenin, three (75%) demonstrated capsular invasion.
Inclusion of these cases was likely to have affected the relation-
ship. With regard to the lack of correlation with other types of
invasion, only a few lesions were positive for the vascular type,
making analysis difficult while conversely lymphatic invasion was
frequent.
Interestingly, both E-cadherin and catenins were normally
expressed in six of 22 cases of capsular invasion, 14 of 31 with
lymphatic invasion and three of eight with vascular invasion. It
has been suggested that abnormal tyrosine phosphorylation of
b-catenin regulated by c-erbB-2 protein or c-met protein may
cause transient dysfunction of E-cadherin-mediated cell adhesion
(Shibata et al, 1996). In prostate cancer, amplification and over-
expression of c-erbB-2 are rare (Pisters et al, 1995), but expression
of c-met is frequently detectable immunohistochemically
(Fournier et al, 1995). A possible explanation for the detachment
of cancer cells from primary cancer nests in these cases is that
abnormal tyrosine phosphorylation of b-catenin had occurred.
Reduced expression of E-cadherin and a-catenin appears to be
associated with tumour progression and poor survival (Umbas et
al, 1994, 1997; Richmond et al, 1997). Umbas et al (1994) have
reported that progression after radical prostatectomy occurred in
67% (10 of 15) cases with aberrant E-cadherin expression, and in
only 4% (one of 27) with normal E-cadherin staining. In the
present study the period of observation is not sufficiently long
(mean 18 months) to allow an assessment of prognosis. Long-term
follow-up is continuing.
Our data indicate that three types of catenin may be useful
predictive markers for biological aggressiveness of prostate
cancer. We take a great interest in the question whether capsular
invasion of prostate cancer can be more accurately predicted by
immunostaining of catenins for biopsy materials before treatment.
However, E-cadherin may be inadequate for this purpose despite
the fact that this molecule has been regarded as a useful prognostic
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Table 3 Relationship between expression of E-cadherin and catenins and the Gleason score
Gleason E-cadherin a-catenin b-catenin g-catenin
score
N A Significance N A Significance N A Significance N A Significance
3 – 4 3 0 30 30 3 0
5–7 15 7 c2 = 8.95 14 8 c2 = 7.82 16 6 c2 = 8.46 18 4 c2 = 6.40
8–10 6 14 P = 0.011 6 14 P = 0.020 7 13 P = 0.015 10 10 P = 0.041
N, normal expression; A, aberrant expression.
Table 4 Relationship between expression of E-cadherin and catenins and capsular invasion
E-cadherin a-catenin b-catenin g-catenin
All cases c2 = 2.67 c2 = 6.41 c2 = 8.09 c2 = 7.17
(n = 45) P = 0.102 P = 0.011 P = 0.004 P = 0.007
Moderately c2 = 2.79 c2 = 1.47 c2 = 4.77 c2 = 5.86
differentiated casesa P = 0.094 P = 0.224 P = 0.028 P = 0.015
(n = 22)
aGleason score 5–7.marker. Actually it has been reported that half of the advanced
prostate cancers with normal E-cadherin but aberrant a-catenin
expression showed progression (Umbas et al, 1997). We have
confirmed that formalin-fixed, paraffin-embedded specimens can
be utilized for immunostaining of catenins (data not shown) and a
prospective study using needle biopsy specimens is now in
progress.
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